Hepatitis C Treatment Resources

Treating HCV in the Community GI Setting – How to Make it Work

Gastroenterologists recognize treating HCV is the right thing to do but may face clinical challenges managing HCV patients. That’s why the ACG is offering a new resource for the busy GI practice. Developed by an Expert Task Force on Hepatitis C, chaired by Dr. Mitchell Shiffman, the College is proud to introduce these materials which feature:

ACG Hepatitis C Resource Kit

The ACG Hepatitis C Treatment Resource Kit covers clinical management issues such as:

  • Pre-Treatment Assessment
  • Initial Work-up
  • Patient Counseling and Education
  • Documenting Response to Treatment
  • Monitoring Parameters for HCV RNA During Treatment
  • Laboratory Studies During Therapy
  • Use of Growth Factors
  • Managing Depression
  • Managing Cytopenias

Video Slide Presentation by Dr. Mitchell Shiffman

“Maximizing Practice Efficiency from the Treatment of Hepatitis C Patients”

Customizable Resources for Your Patient

Download Templates, Forms, Patient Teaching Tools and Trackers to customize for use in your practice.

ACG HCV Forms | pdf
ACG HCV Forms | Word
ACG HCV Treatment Flowsheet | Excel

Patient Brochures

Tips to Lesson Common Side Effects of HCV Therapy
Commonly Asked Questions About Chronic Hepatitis C
Hepatitis C Treatment and Anemia

HCV: A Major Public Health Challenge

In the United States, hepatitis C virus (HCV) is the most common chronic blood-borne infection, the most common cause of chronic liver disease contributing to progressive liver fibrosis, cirrhosis and liver cancer, and is the most frequent cause for liver transplantation. Primary care physicians are identifying patients with chronic viral hepatitis C at an increasing rate. Moreover, as new and more effective treatments for chronic HCV become available, more patients will seek treatment.

Hepatologists currently treat the majority of patients with chronic HCV, but are typically located at large medical centers and in most cases, will be unable to expand their clinical practices to care for the increase in patients with HCV seeking medical care. As a result, many experts and medical societies like the ACG believe that community-based gastroenterologists will begin to manage and treat an increasing number of patients with chronic HCV in the future. This ACG Hepatitis C Treatment Resource Kit was developed to assist community-based gastroenterologists achieve this goal.

Reason for Hope

The current standard of care, peginterferon plus ribavirin, results in a sustained viral response in fewer than 45 percent of patients.  However, the introduction of new, direct acting anti-viral agents (DAA) against HCV when combined with peginterferon and ribavirin will increase sustained virologic response and “cure” HCV in 70-75 percent of patients.  These new treatments will significantly change the landscape of HCV therapy and lead to a marked reduction in mortality from chronic HCV within 5 years after these medications are introduced.  The ACG is committed to support GI practices in meeting the future challenge of HCV therapy by providing the tools and resources needed to integrate HCV treatment into a busy GI practice.

Readiness is All

An urgent need exists for community gastroenterologists to increase their knowledge and maximize positive outcomes in the management and treatment of chronic hepatitis C.  ACG’s fundamental objective in offering these materials is to improve gastroenterologists’ overall capacity to frame effective disease management strategies for Hepatitis C in community GI practices.  These materials aim to help GI physicians optimize outcomes of antiviral therapy and provide strategies for managing patients who have not previously been treated for HCV, as well as those patients who have previously failed conventional treatment with peginterferon and ribavirin.

Integrating Treatment of HCV in a Busy GI Practice

To address the need to increase practice compatibility with HCV treatment, ACG has developed this Hepatitis C Treatment Resource Kit which provides ACG members with sound strategies to make their GI practices “user friendly” for HCV patients.

The kit addresses practice management needs, and offers flow sheets, trackers and templates to help manage HCV patients.  All of the materials are designed to help GI practices streamline patient monitoring with the goal of saving time and maximizing physician interaction during patient encounters.

How to Use the ACG Hepatitis C Treatment Resource Kit

The ACG Institute for Clinical Research & Education convened an expert Task Force to develop resources for managing HCV patients. The group collaborated on a variety of templates and sample patient education forms included in this booklet which can be downloaded and customized for a GI practice.  To maximize the usefulness of these materials, and create the greatest flexibility, all of the patient education tools are also provided in a format that can be edited and personalized to meet the specific requirements of your practice and your patients.

Samples of the ACG patient education pamphlets featured in the kit are also available to ACG members, with 20 copies of each free of charge to ACG members, who can also order additional quantities for office use priced at $25.00 for 100 copies, including shipping.  Please allow 3 to 4 weeks for delivery.

ACG HCV Expert Task Force

  • Chair, Mitchell L. Shiffman, MD, FACG, Director, Liver Institute of Virginia, Bon Secours Health System, Newport News, VA
  • David E. Bernstein, MD, FACG, Chief of Gastroenterology, Hepatology and Nutrition, North Shore University Hospital and Long Island Jewish Hospital, Long Island, NY
  • Ira L. Flax, MD, FACG, Digestive and Liver Specialists of Houston, TX
  • Jorge L. Herrera, MD, FACG, Director, Section on Hepatology, Professor of Medicine, University of South Alabama, Mobile, AL
  • Paul Y. Kwo, MD, Associate Professor of Clinical Medicine, Indiana University Department of Medicine, Indianapolis, IN
  • Harry A. Sarles, Jr., MD, FACG, Digestive Health Associates of Texas, Dallas, TX
  • Zobair M. Younossi, MD, MPH, FACG, Executive Director, Center for Liver Diseases at Inova Fairfax Hospital, Falls Church, VA; Vice President for Research, Inova Health System, Falls Church, VA

Materials for physicians and patients included on this Web site developed by the ACG Institute for Clinical Research & Education ACG Hepatitis C Task Force. Printing and distribution, including electronic publication here, supported by an educational grant from Roche.